Partnership Efforts – Their Potential to Reduce the Challenges that Confront Regulators and Pharmaceutical Industry

Author(s): Sandeep Kumar Dhiman , Vikram Gummadi , Harish Dureja* .

Journal Name: Applied Clinical Research, Clinical Trials and Regulatory Affairs

Volume 6 , Issue 1 , 2019

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Background: The healthcare is a highly regulated sector as it serves billions of population globally. The two imperative pillars of this sector are pharmaceutical industry and health regulatory authorities. While the industry acts as a supplier in this sector, regulators provide governance to ensure quality, safety and efficacy of the healthcare products. Even though organizational objectives of these two stakeholders are different, the by and large goal is to improve health outcomes for populations. Both these entities are confronted by an assortment of challenges.

Objectives: This study aims to draw attention towards such pain points and the potential of collaboration and coordination efforts between these entities to mitigate these challenges. The industry faces challenges that are driven by business needs and regulations. The major challenges faced by the regulators are driven by the needs to ensure the safety, quality and efficacy of health care products. Some of these challenges may have an overlap. Market scenario, patent/ exclusivities/return on investment issues, development costs, cost containment, quality and GMP, scientific discovery productivity, novel therapies and technology, regulatory framework, counterfeiting, supply chain challenges, Product life cycle management (PLM), patient centricity approach, resources and financial constraints, process issues, protection of the public health, contemporizing and growth of regulatory framework, political scenario in the country/region, unethical clinical trials and research, healthcare policies, citizen participation, pharmacovigilance and safety measures comprise a non-exhaustive list of challenges that confront industry and regulators. Health authorities need to partner amongst them and with Pharmaceutical industry and continue to innovate for novel ways of working to conquer these challenges. Organizations of international/ regional repute are known for their unique contribution in regulating the healthcare sector. These bodies have helped to improve access to safe medicines more widely by harmonization of drug quality, safety, and efficacy standards. These coordinated efforts have the potential to reduce the numbers of challenges that confront the healthcare sector.

Conclusion: The pharmaceutical industry and health regulators need to partner to achieve common goal of healthcare. There is a growing need for these parties to come together on common platforms and collaborate. The success of the strategies and approaches intended to deal with these challenges depends upon strategic-level leadership and new ways of collaborative working, which creates a room for potential synergies.

Keywords: Collaboration, coordination, partnership, regulators, pharmaceutical industry, challenges, solutions, confront, harmonization, healthcare.

[1]
Regulatory framework and challenges in indian pharmaceutical sector. 2013. [Cited: 2017 August 12]; Available from: http://www.cutsccier.org/pdf/ Regulatory_Framework_and_Challenges_in_Indian_ Pharmaceutical_Sector.pdf
[2]
Pharmaceutical regulatory agencies and organizations around the world: Scope and challenges in drug development. 2011. [Cited: 19 August 2017]; Available from: http://www. pharmatutor.org/articles/pharma-ceutical-regulatory-agencies-and-organizations-around-world-scope-challenges-in-drug-development
[3]
Pharmaceuticals: regulatory agencies. 2017. [Cited: 05 August 2017]; Available from: https://globaledge. msu.edu/industries/pharmaceuticals/regulatory-agencies
[4]
List of globally identified websites of medicines regulatory authorities. 2012. [Cited: 05 August 2017]; Available from: http://www.who.int/medicines/areas/ quality_safety/regulation_legislation/list_mra_web-sites_nov2012.pdf
[5]
Important international guidelines and regulatory bodies. 2017. [Cited: 05 August 2017]; Available from: http://www.ipapharma. org/Regulations.aspx
[6]
Beitsch LM, Brooks RG, Grigg M, Menachemi N. Structure and functions of state public health agencies. Am J Public Health 2006; 96(1): 167-72.
[7]
Promoting access to medical technologies and innovation intersections between public health, intellectual property and trade. 2017. [Cited: 01 October 2017]; Available from: https://www.wto.org/english/ tratop_e/trips_e/trilatweb_e/trilat_web_13_e.htm
[8]
Regulatory collaboration: The international coalition of medicines regulatory authorities (ICMRA). 2015. [Cited: 18 August 2017]; Available from: http://www. who.int/medicines/publications/druginformation/WHO_DI_29-1_RegulatoryCollaboration.pdf
[9]
Pharma’s next challenge. 2015. [Cited: 19 August 2017]; Available from: www.mckinsey.com/indus-tries/pharmaceuticals-and-medical-products/our-insi-ghts/pharmas-next-challenge
[10]
Prajapati V, Dureja H. Product lifecycle management in pharmaceuticals. J Med Market: Device Diagn Pharm Market 2012; 12(3): 150-8.
[11]
Saha CN, Bhattacharya S. Intellectual property rights: An overview and implications in pharmaceutical industry. J Adv Pharm Technol Res 2011; 2(2): 88-93.
[12]
Convergence of health and pharma: The whole is greater than the sum of the parts. 2014. [Cited: 05 August 2017]; Available from: https://www.cgi.com/ sites/default/files/white-papers/cgi-health-pharma-convergence-white-paper.pdf
[14]
Challenges facing the pharmaceutical industry into the future. 2015. [Cited: 05 August 2017]; Available from: http://www.complian ceteaminc.com/chall-enges-facing-pharmaceutical-industry-future/
[15]
Challenges in global biosimilar development: A regulatory perspective. 2015. [Cited: 05 August 2017]; Available from: http://www. contractpharma.com/ issues/2015-06-01/view_featur-es/challenges-in-global-biosimilar-development-a-regulatory-perspective
[16]
Pharma industry trends pose new regulatory & recall challenges. 2016. [Cited: 12 August 2017]; Available from: https://www.pharmpro.com/news/2016/02/ pharma-industry-trends-pose-new-regulatory-recallchallenges.
[17]
Biopharmaceutical manufacturing: The challenge of global regulatory compliance. 2008. [Cited: 18 August 2017]; Available from: http://www.pharm-tech.com/biopharmaceutical-manu-facturing-challe-nge-global-regulatory-compliance
[18]
Challenges and opportunities for pharma industry. 2012. [Cited: 05 August 2017]; Available from: http://pharmabiz.com/Article Details.aspx? aid=696 54&sid=9.
[19]
Indian pharmaceutical industry: Regulatory challenges. 2013. [Cited: 05 August 2017]; Available from: http://pharmabiz.com/ArticleDetails.aspx?aid =79470&sid=21.
[20]
Venkatesh M, Bairavi VG, Sasikumar KC. Generic antibiotic industries: Challenges and implied strategies with regulatory perspectives. J Pharm Bioallied Sci 2011; 3(1): 101-8.
[21]
Regulatory issues in the indian pharmaceutical industry. 2008. [Cited: 05 August 2017]; Available from: http://www.nistads.res.in/indiasnt2008/t4industry/ t4ind18.htm
[22]
Global regulation and investigations challenges ahead in 2015. [Cited: 12 August 2017]; Available from: http://www.nortonrose-fulbright.com/knowledge/pub-lications/125042/global-regulation-and-investigations -challenges-ahead-in-2015.
[23]
The top 10 issues for the pharma industry in 2017. [Cited: 19 August 2017]; Available from: https://connect.dcat.org/blogs/patricia-van-arnum/201 7/01/17/the-top-10-issues-for-the-pharma-industry-in-2017#.Wca0TMgjHIW
[24]
Putting the patient first: How the life sciences industries might look in 2018. 2013. [Cited: 29 September 2017]; Available from: http://www.kinapse. com/media/1112/putting-the-patient-first-how-the-life-sciences-industries-might-look-in-2018.pdf
[25]
How can regulatory affairs be more patient-centric? 2013. [Cited: 29 September 2017]; Available from: http://www.kinapse.com/media/1108/how-regulatory-affairs-can-be-more-patient-centric.pdf
[26]
Asano K, Tanaka A, Sato T, Uyama Y. Regulatory challenges in the review of data from global clinical trials: The PMDA perspective. Clin Pharmacol Ther 2013; 94(2): 195-8.
[27]
Pezzola A, Sweet CM. Global pharmaceutical regulation: The challenge of integration for developing states. Global Health 2016; 12: 85.
[28]
Frankish CJ, Kwan B, Ratner PA, Higgins JW, Larsen C. Challenges of citizen participation in regional health authorities. Soc Sci Med 2002; 54: 1471-80.
[29]
Multinational: Programs and policies: Other regional & international organizations. 2013. [Cited: 05 August 2017]; Available from: http://alttox.org/mapp/ regulatory-policy/multinational-programs-policies/ mn-other-regional-international-organizations/
[30]
Convergence of regulatory expectations, review and approval. 2016. [Cited: 01 October 2017]; Available from:
[http://dx.doi.org/10.17226/21853]
[31]
7 things to love about the regulatory convergence. 2017. [Cited: 01 October 2017]; Available from: http://www.raps.org/Regulatory-Focus/RAPS-Latest/ 2017/07/06/22963/7-Things-to-Love-About-the-Regulatory-Convergence/
[32]
Hosoda N, Ishiji H. Japan: Key considerations for successful PMDA consultation meetings. Reg Rappo 2015; 12(3): 4-7.
[33]
Controlled correspondence related to generic drug development: Guidance for industry. 2015. [Cited: 01 October 2017]; Available from: https://www.fda.gov/ downloads/drugs/guidances/ucm411478.pdf
[34]
Putzeist M, Mantel-Teeuwisse AK, Wied CCG, Hoes AW, Leufkens HG. Regulatory scientific advice in drug development: Does company size make a difference? Eur J Clin Pharmacol 2011; 67: 157-64.
[35]
First regional ICH training on CMC. 2017. [Cited: 01 October 2017]; Available from: http://www.diaglobal. org/en/resources/news#article=5632e5ff-3c07-4a05-b664-479d83317633
[36]
Physician education improves health for patients - and for industry. 2015. [Cited: 01 October 2017]; Available from: http://www.dia-global.org/en/resou-rces/news#article=fd36eb1e-4865-4e03-a14a-65df42 5a94e2.


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 6
ISSUE: 1
Year: 2019
Page: [7 - 17]
Pages: 11
DOI: 10.2174/2213476X06999190206120109

Article Metrics

PDF: 27
HTML: 5
EPUB: 1